Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147576
Status:
COMPLETED
Last Update Posted:
2012-10-02
First Post:
2005-09-02
Brief Title:
Study To Examine Effect Of CP-866087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Randomized Placebo-Controlled Parallel Group Study Comparing Effect Of Three Doses Of CP-866087 And Naltrexone On Acute Alcohol Consumption And Craving After Seven Days Of Treatment In Alcohol Dependent DSM IV Subjects Who Are Not Currently Seeking Treatment
Status:
COMPLETED
Status Verified Date:
2012-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Test the hypothesis that increasing doses of CP-866087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866087 in alcohol dependent subjects compared to placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None